Akeso Full Year 2022 Earnings: Misses Expectations
Akeso (HKG:9926) Full Year 2022 Results
Key Financial Results
- Revenue: CN¥837.7m (up 271% from FY 2021).
- Net loss: CN¥1.17b (loss widened by 8.7% from FY 2021).
- CN¥1.42 loss per share (further deteriorated from CN¥1.32 loss in FY 2021).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Akeso Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 1.3%. Earnings per share (EPS) also missed analyst estimates by 4.8%.
Looking ahead, revenue is forecast to grow 25% p.a. on average during the next 3 years, compared to a 34% growth forecast for the Biotechs industry in Hong Kong.
Performance of the Hong Kong Biotechs industry.
The company's shares are up 17% from a week ago.
You should learn about the 1 warning sign we've spotted with Akeso.
Valuation is complex, but we're helping make it simple.
Find out whether Akeso is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.View the Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes therapies.
High growth potential with adequate balance sheet.